Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 8 - LEE011 for Patients With CDK4/6 Pathway Activated Tumors

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ribociclib (Primary)
Indications Adrenal cancer; Advanced breast cancer; Bladder cancer; Haematological malignancies; Head and neck cancer; Mesothelioma; Penile cancer; Sarcoma; Solid tumours; Squamous cell cancer; Thyroid cancer
Focus Therapeutic Use
Acronyms SIGNATURE
Sponsors Novartis Pharmaceuticals

10 Jun 2018 Status changed from active, no longer recruiting to completed.
22 Sep 2017 Planned End Date changed from 15 Apr 2018 to 31 Oct 2017.
22 Sep 2017 Planned primary completion date changed from 15 Apr 2018 to 31 Oct 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com